What is Poxel?
Poxel operates at the intersection of advanced biotechnology and metabolic science, focusing on the development of innovative treatments for serious chronic conditions. The company's core competency lies in its robust pipeline targeting liver and rare metabolic disorders, a market segment characterized by high unmet medical needs. Beyond its internal R&D efforts, Poxel benefits from a diversified revenue model, which includes royalty-related income from a partnered diabetes therapy currently commercialized in Japan. This dual-pronged strategy—combining clinical innovation with established commercial partnerships—positions Poxel as a resilient player in the biopharma space, capable of navigating the complexities of drug development while maintaining a sustainable financial foundation.
How much funding has Poxel raised?
Poxel has raised a total of $71.4M across 6 funding rounds:
Series A
$21M
Series B
$13.5M
Share Placement
$19.4M
Unspecified
$7M
Debt
$6.1M
Other Financing Round
$4.3M
Series A (2010): $21M with participation from Edmond de Rothschild
Series B (2014): $13.5M, investors not publicly disclosed
Share Placement (2020): $19.4M supported by Undisclosed
Unspecified (2020): $7M featuring BNP Paribas and Bpifrance
Debt (2022): $6.1M backed by IRIS
Other Financing Round (2026): $4.3M with participation from IPF Partners
Key Investors in Poxel
IPF Partners
IPF Partners is a prominent alternative financing provider focused exclusively on the healthcare sector, offering tailored debt and equity financing solutions for biopharma and medtech companies.
BNP Paribas
BNP Paribas is a leading international banking group that provides comprehensive financial services, including corporate and institutional banking, to support innovation and long-term growth.
Bpifrance
Bpifrance is a French public investment bank that supports companies at every stage of their development through credit, guarantees, and equity financing.
What's next for Poxel?
With the successful closure of this major strategic investment, Poxel is well-positioned to execute its next phase of clinical development. The company is expected to prioritize the advancement of its lead candidates through critical trial milestones, potentially expanding its therapeutic footprint in the metabolic space. Furthermore, the influx of capital provides the necessary liquidity to optimize operational efficiencies and explore potential licensing or collaborative opportunities that could enhance its existing portfolio. As the biopharmaceutical industry continues to prioritize precision medicine and targeted therapies, Poxel's focus on metabolic dysfunction remains a high-growth area, offering significant potential for future clinical breakthroughs and long-term commercial expansion.
See full Poxel company page
